NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Universal Diagnostics

Universal Diagnostics

Private
SevilleHealthcare & Life Scienceshttps://www.universaldx.com/

Last Round

Series C

Jan 20, 2026

Total Funding Raised

$268.49M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Universal Diagnostics is a biotech company that develops minimally-invasive, blood-based liquid biopsy tests for the early detection of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

liquid biopsymulti-cancer early detectioncolorectal cancer screeningMCEDmolecular diagnosticsblood-based cancer testnext-generation sequencingNGSbioinformaticsprecision medicinecancer biomarker discoveryclinical diagnosticsAI diagnosticsnon-invasive screeningPremarket ApprovalPMA

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Universal Diagnostics Comparables

Compare Universal Diagnostics with similar companies based on industry and business-model similarity.

Universal Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Universal Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 20, 2026
DebtFeb 27, 2025
Series BAug 7, 2024
DebtFeb 27, 2024
Series BNov 20, 2023
Angel
Aug 16, 2018

Key People

Founding team and executive leadership

Diego Broseta

Chief Financial Officer

Executive Team

Christian Hense

Chief Operating Officer (COO)

Executive Team

Universal Diagnostics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Hiring for Clinical Research Associate indicates diagnostic test trials are in progress.

  • Jan 1, 2026

    Undergoing FDA Premarket Approval for Class III diagnostic device Signal-C.

Universal Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Universal Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Universal Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeville
Employee Range125
Year Founded2012
Last FundingJan 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.